Skip to content

Niven Mehra

  • MD, PhD
  • Postdoctorate researcher
  • Radboud University Radboud Institute for Molecular Life Sciences
  • 10h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 571CitationsNumber of citations received by Niven's publications. Updated daily.

Groups

  • PCTTG
    PCTTG

Co-authors (116)

  • Minke Smits
  • spyridon sideris

Publications (5)

  • A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer

    • Benoist G
    • van der Doelen M
    • ter Heine R
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

    • Mehra N
    • Dolling D
    • Sumanasuriya S
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer

    • Degeling K
    • Schivo S
    • Mehra N
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Drug-drug interaction potential in men treated with enzalutamide: Mind the gap

    • Benoist G
    • van Oort I
    • Smeenk S
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

    • Massard C
    • Mateo J
    • Loriot Y
    • et al.
    N/AReaders
    N/ACitations
    Get full text

Editorships

ESMO Publishing working group

Member PWG

2014 - Present

Professional experience

Postdoctorate researcher

Radboud Universiteit

June 2016 - Present

Medical Oncologist

Radboudumc, Department of Medical Oncology

June 2016 - Present